6118 — Austar Lifesciences Share Price
Last trade - 00:00- HK$399.81m
- HK$651.27m
- CNY1.50bn
- 26
- 77
- 57
- 56
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.47 | ||
| Price to Tang. Book | 0.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.25 | ||
| EV to EBITDA | 6.93 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.93% | ||
| Return on Equity | 2.06% | ||
| Operating Margin | 2.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 1,295.98 | 2,015.03 | 2,156.87 | 1,763.73 | 1,500.4 | n/a | n/a | 7.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +214.45 | +206.49 | -4.51 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Austar Lifesciences Ltd is a holding company that mainly engaged in providing integrated engineering solutions, and manufacturing and distributing pharmaceutical equipment and consumables. The Company operates six segments: Fluid and Bioprocess Systems segment, Cleanroom and Automation Control and Monitoring Systems segment, Powder and Solid Systems segment, GMP Compliance Services segment, Life Science Consumables segment, and Distribution and Agency of Pharmaceutical Equipment segment. The Company's products include clean utility equipment and systems, bioprocess equipment and systems, powder and solid equipment and systems, pharmaceutical process contamination control products, packaging and closed transport products, biosafety and laboratory animal equipment and consumables, and others.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 9th, 2014
- Public Since
- November 7th, 2014
- No. of Employees
- 1,445
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 512,582,000
- Address
- Rooms 2010-2013,, SHANGHAI
- Web
- https://www.austar.com.cn/
- Phone
- Auditors
- Moore CPA Limited
Upcoming Events for 6118
Similar to 6118
Acotec Scientific Holdings
Stock Exchange of Hong Kong Limited
Beijing Airdoc Technology Co
Stock Exchange of Hong Kong Limited
AK Medical Holdings
Stock Exchange of Hong Kong Limited
AMCO United Holding
Stock Exchange of Hong Kong Limited
Angelalign Technology
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 24:18 UTC, shares in Austar Lifesciences are trading at HK$0.78. This share price information is delayed by 15 minutes.
Shares in Austar Lifesciences last closed at HK$0.78 and the price had moved by -12.36% over the past 365 days. In terms of relative price strength the Austar Lifesciences share price has underperformed the FTSE Developed Asia Pacific Index by -11.36% over the past year.
There is no consensus recommendation for this security.
Find out moreAustar Lifesciences does not currently pay a dividend.
Austar Lifesciences does not currently pay a dividend.
Austar Lifesciences does not currently pay a dividend.
To buy shares in Austar Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.78, shares in Austar Lifesciences had a market capitalisation of HK$399.81m.
Here are the trading details for Austar Lifesciences:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6118
Based on an overall assessment of its quality, value and momentum Austar Lifesciences is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Austar Lifesciences. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +18.07%.
As of the last closing price of HK$0.78, shares in Austar Lifesciences were trading +14.06% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Austar Lifesciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Austar Lifesciences' directors